Santreva-ATK System
Femoropopliteal Chronic Total Occlusions (CTOs) in Peripheral Artery Disease
Pivotal Trial CompletedActive
Key Facts
Indication
Femoropopliteal Chronic Total Occlusions (CTOs) in Peripheral Artery Disease
Phase
Pivotal Trial Completed
Status
Active
Company
About AngioSafe
AngioSafe is a private, clinical-stage medical device company pioneering a new approach to endovascular revascularization for peripheral artery disease (PAD), specifically targeting chronic total occlusions (CTOs). Its core innovation is the Atheroplasty™ platform, which combines intraplaque cutting, compression, and channel formation in a single, wire-free device, aiming to simplify complex procedures and reduce complications like embolism and dissection. The company's technology is supported by positive data from the RESTOR-1 pivotal trial, positioning it to address a significant unmet need in the large and growing peripheral vascular market.
View full company profile